SGLT2 inhibitors in older adults: overcoming the age barrier

Publication DOI: https://doi.org/10.1016/S2666-7568(23)00039-9
Divisions: College of Health & Life Sciences > School of Biosciences
College of Business and Social Sciences > Aston Business School > Aston India Centre for Applied Research
College of Health & Life Sciences
College of Health & Life Sciences > Chronic and Communicable Conditions
Additional Information: Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to: Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154. https://doi.org/10.1016/S2666-7568(23)00032-6
Uncontrolled Keywords: Aged,Hypoglycemic Agents - therapeutic use,Humans,Diabetes Mellitus, Type 2 - drug therapy,Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Publication ISSN: 2666-7568
Last Modified: 16 May 2024 07:21
Date Deposited: 17 Apr 2023 09:13
Full Text Link: https://www.the ... 0039-9/fulltext
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Letter
Published Date: 2023-04
Accepted Date: 2023-03-06
Submitted Date: 2023-03-06
Authors: Bellary, Srikanth (ORCID Profile 0000-0002-5924-5278)
Barnett, Anthony H

Export / Share Citation


Statistics

Additional statistics for this record